Study #2020-0135
A Phase 1b Open-label Study Investigating theSafety, Tolerability, Pharmacokinetics, andEfficacy of Administration of Blinatumomab inCombination With AMG 404 for the Treatment ofAdults With Relapsed or Refractory B CellPrecursor Acute Lymphoblas
MD Anderson Study Status
Enrolling
Treatment Agent
Blinatumomab, AMG 404, Dexamethasone Premedication
Description
The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined with continuous intravenous infusion (cIV) blinatumomab.
Information and next steps
Disease:
Acute Lymphoblastic Leukemia
Study phase:
I
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.